Site News

Added 19 hours ago Drug news

Phase III study of Intuniv (guanfacine hydrochloride prolonged release) meets primary endpoint in adults with attention deficit hyperactivity disorder.- Shire + Shionogi.

Shire and Shionogi announced that a Phase III study evaluating Intuniv (guanfacine hydrochloride prolonged release) in adult patients with attention...

Added 19 hours ago Drug news

EU approves Rydapt (midostaurin) for adults with newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive and for the treatment of adults with aggressive systemic mastocytosis.- Novartis.

Novartis has announced that the European Commission approved Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers. Rydapt is approved...

Added 19 hours ago Drug news

APOLLO phase III study of ALN TTR02 (patisiran) in hereditary ATTR amyloidosis with polyneuropathy meets primary endpoints.- Sanofi Genzyme + Alnylam Pharmaceuticals.

Sanofi Genzyme and Alnylam Pharmaceuticals announced that the APOLLO Phase III study of ALN TTR02 (patisiran), for patients with hereditary...

Added 19 hours ago Drug news

ThromboGenics NV regains rights to Jetrea (ocriplasmin), a treatment for vitreomacular adhesion and vitreomacular traction, from Novartis.

ThromboGenics NV a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced that...

Added 19 hours ago Drug news

Phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) meets primary endpoint in chronic obstructive pulmonary disease.- GlaxoSmithKline + Innoviva.

GlaxoSmithKline and Innoviva announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI)...

Added 19 hours ago Drug news

Medtronic launches Intellis spinal cord neurostimulation platform which includes the world’s smallest fully implantable spinal cord neurostimulator to treat pain.

Medtronic received 510(k) FDA approval on 11 July 2017 and is now releasing in the U.S. its Intellis spinal cord...

Added 1 day ago Drug news

New data from Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the HeartLogic Heart Failure Diagnostic to predict impending heart failure (HF) decompensation.- Boston Scientific.

Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance...

Added 1 day ago Drug news

FDA approves triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), as Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with COPD.-GSK + Innoviva.

GlaxoSmithKline plc and Innoviva, Inc. announced that the FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under...

Added 1 day ago Industry news

Teva disposes of womens health businesses to CVC Capital Partners Fund VI and to Foundation Consumer Healthcare.

Teva Pharmaceutical Industries Ltd.,announced it has entered into two agreements to sell the remaining assets of its specialty global women’s...

Search all news articles